top of page
  • Facebook
  • Twitter
  • Instagram
Singh Headshot_edited.jpg

Manpreet Singh, MD, MS
Robert H. Putnam Endowed Chair in Bipolar Research and Treatment
University of California Davis, School of Medicine

Treatment of Mood Disorders in Children and Adolescents
Friday, February 12, 2027
9:00 AM - 10:00 AM

Dr. Singh is the Robert H. Putnam Endowed Chair in Bipolar Research and Treatment at University of California Davis. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center, when she also completed a Masters of Science in Clinical Research Design and Statistical Analysis. 

​

Then, after postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined Stanford University's professoriate, where she conducted family studies integrating neuroimaging, cognitive, genetic, behavioral, and peripheral biomarker data characterizing risk for and resilience from developing bipolar and other mood disorders. Dr. Singh's work at UC Davis has a three-fold mission: 1) to investigate the origins and pathways for developing major mood disorders and in processes that protect and preserve function after disorder onset; 2) to recruit, train, and sustain the next generation of basic, translational, and clinical researchers in psychiatry; and 3) to evolve clinical care in ways that lead to better outcomes. Taking a translational medicine approach, Dr. Singh’s research aims to address unmet clinical needs in mood and related disorders through bridging fundamentals in basic science to clinical practice.

Lecture Summary:

This presentation will review current approaches to the treatment of mood disorders in children and adolescents, with a focus on unipolar major depressive disorder and bipolar disorder. The session will examine differences in the efficacy, tolerability, and expected course of response among commonly used pharmacologic treatments, while also addressing considerations for sequencing and tapering therapies. The presentation will further explore the challenges posed by clinical heterogeneity and limited treatment response in youth and will highlight emerging pharmacologic and nonpharmacologic therapies currently under investigation.

​Goals and Learning Objectives:

  • Review general psychopharmacology considerations for children and adolescents.

  • Describe evidence-supported management of Unipolar Major Depressive Disorder (MDD) and Bipolar disorder (BD) in youth

  • Gain exposure to novel therapeutics for youth with mood disorders currently undergoing development.​

​

Disclosures:

Advisory Board : AbbVie Inc., Alkermes, Almatica, Axsome, Boehringer-Ingelheim, Bristol Myers Squibb, Johnson and Johnson, Karuna Therapeutics (past), Neumora (past), and Supernus
 

Grant/Research Support : National Institutes of Health, the Patient Centered Outcomes Research Institute, Advanced Neuromodulation Systems/Abbott, AbbVie Inc, Alto Neuroscience, and IntraCellular Therapies/Johnson & Johnson 
 

Consultant : Alto Neuroscience (past)
 

Royalty : Thrive Global, American Psychiatric Association Publishing
 

Other Financial Benefit : Honoraria from the American Academy of Child and Adolescent Psychiatry for Journal Editor role

bottom of page